• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Valneva (Group)

Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various clinical-stage vaccines in development including unique vaccines against Lyme disease and chikungunya. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 490 employees. *

 

	Start	2013-05-28 merged
	Predecessor	Vivalis (Group)
	Industry	avian (bird) production technology (transgenic)
	Industry 2	vaccine
	Person	Lingelbach, Thomas (Intercell 201106– CEO before COO before 2001– Chiron Behring)
	Person 2	Grimaud, Franck (Vivalis 200702 CEO)
	Region	Lyon
	Country	France
	Street	6 rue Alain Bombard Campus Bio-Quest
	City	44800 Saint-Herblain
		Address record changed: 2020-12-02
Basic data	Employees	E: 501 to 1,000 (2019-12-31)
	Currency	EUR
	Annual sales	126,196,000 (revenues, total, consolidated (2019) 2019-12-31)
	Profit	-1,744,000 (2019-12-31)
	Cash	64,439,000 (2019-12-31)
		* Document for �About Section�: Valneva S.E.. (1/9/20). "Press Release: Valneva Expands its Commercial Operations with the Opening of its French Commercial Office". Saint-Herblain.
		Record changed: 2020-05-09

Advertisement

More documents for Valneva (Group)

• [1] Valneva S.E.. (5/10/21). "Press Release: Valneva Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $107.6 Million". Saint-Herblain....
• [2] Valneva S.E.. (4/29/21). "Press Release: Valneva Announces Launch of Proposed Global Offering, Start of the Roadshow and Nasdaq Listing". Saint-Herblain....
• [3] Valneva S.E.. (4/6/21). "Press Release: Valneva Reports Positive Phase 1/2 Data for Its Inactivated, Adjuvanted COVID-19 Vaccine Candidate, VLA2001". Saint-Herblain....
• [4] Valneva S.E.. (11/10/20). "Press Release: Valneva Announces Plans for Extraordinary General Meeting to Prepare for Potential US IPO". Saint-Herblain....
• [5] Valneva S.E.. (9/8/20). "Press Release: Valneva Initiates Phase 3 Clinical Study for its Chikungunya Vaccine Candidate VLA1553". Saint-Herblain....
• [6] Valneva S.E.. (7/20/20). "Press Release: Valneva Confirms Participation in UK Government COVID-19 Vaccine Response Program". Saint-Herblain....
• [7] Valneva S.E.. (6/18/20). "Press Release: Valneva and Bavarian Nordic Announce Marketing and Distribution Partnership". Saint-Herblain....
• [8] Valneva S.E.. (4/30/20). "Press Release: Valneva and Pfizer Announce Collaboration to Co-Develop and Commercialize Lyme Disease Vaccine, VLA15". Saint-Herblain & New York, NY....
• [9] Valneva S.E.. (4/22/20). "Press Release: Valneva and Dynavax Announce Collaboration to Advance Vaccine Development for COVID-19". Saint-Herblain & Emeryville, CA....
• [10] Valneva S.E.. (2/3/20). "Press Release: Valneva Announces New $85 Million Financing Arrangement with Leading US Healthcare Funds Deerfield and OrbiMed". Saint-Herblain....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.